| Study Name | Description | Trial Category Sort ascending | Trial SubCategory |
|---|---|---|---|
| S2101 | This study is for patients with Stage III or IV, unresectable, recurrent, or metastatic melanoma. This study uses Nivolumab and Cabozantinib to treat patients. | Cancer | Melanoma |
| Agendia FLEX | The purpose of this study is to create a large population based database to identify new gene associations in breast cancer. You must be diagnosed with stage 1, 2 or 3 breast cancer. A report is created that looks at the risk of your cancer spreading over the next 10 years. | Cancer | Breast |
| S1706 | This study is looking at using Olaparib after a masectomy at the same time as radiation vs getting radiation alone to determine if adding the medication provides better results. | Cancer | Breast |
| EAY191-A6 ComboMATCH | The purpose of this study is to see if adding Binimetinib in combination with FOLFOX is more effective treatment. You must be diagnosed with biliary tract cancer with a MAPK pathway gene mutation. | Cancer | Biliary |
| S2200 | The purpose of this study is to compare treatment using cabozantinib with or without atezolizmab. You must be diagnosed with metastatic papillary renal cell cancer. | Cancer | Metastatic Renal Cell |
| EAY191-N5 | This study is for patient's who have HER2+ gynecologic cancers or other solid tumors. Cannot have breast cancer. You must have recurrent disease or progressed on treatment. | Cancer | Her2+ Solid Tumors |
| A151216 (ALCHEMIST) | The purpose of this study is to send tissue for screening of mutations to find targeted therapy for your cancer. You must be diagnosed with stage 1B, stage 2 or stage 3A resectable or completely resected non-small cell lung cancer (NSCLC). | Cancer | Non-Small Cell Lung |
| A022102 | The purpose of this study is to compare effectiveness of mFOLFIRINOX with or without nivolumab and mFOLFOX6 with or without nivolumab . You must have newly diagnosed metastatic HER2 negative gastroesophageal cancer. | Cancer | Esophageal |
| EAY191-E4 ComboMATCH | The purpose of this study is to determine the effectiveness of nilotinib and paclitaxel in patients with prior taxane treated solid tumors. You must have had at least one prior line of therapy in the metastatic setting. | Cancer | Solid Tumors |
| S2212 | The purpose of this study is to compare anthracycline-free, taxane-platinum chemo with pembrolizumab to taxane-platinum-anthracycline chemo with pembrolizumab. This study is for people diagnosed with triple negative breast cancer. | Cancer | Breast |
| EA6141 | The purpose of this study is to compare the effectiveness of Nivolumab, Ipilimumab and Sargramostim vs Nivolumab and Ipilmumab. You must be diagnosed with unresectable stage 3 or stage 4 melanoma. | Cancer | Melanoma |
| A022101 | The purpose of this study is to evaluate radiation, ablation and surgery. You must be diagnosed with metastatic colorectal cancer. The primary tumor must be able to surgically resected. | Cancer | Colorectal |
| EAY191-N2 ComboMATCH | This study is for people diagnosed with hormone receptor positive breast cancer that has spread. A NF1 gene mutation must exist. | Cancer | Metastatic Breast |
| S2302 | This study is comparing Ramucirumab + Pembrolizumab vs standard of care chemo for patients previously treated with immunotherapy. You must be diagnosed with stage 4 or recurrent Non-Small Cell Lung Cancer (NSCLC). | Cancer | Metastatic Non-Small Cell Lung |
| E4512 (sub study A151216) | The purpose of this study is to compare Crizotinib vs observation for patients with a ALK+ Fusion Protein to determine if Crizotinib use results in improved disease-free survival. You must be diagnosed with stage 1B, stage 2 or stage 3A resectable or completely resected non-small cell lung cancer (NSCLC). | Cancer | Non-Small Lung |
| S1703 | This study is looking at overall survival or patients monitored with serum tumor markers veruss usual care. You must be diagnosed with metastatic hormone receptor positive breast cancer. | Cancer | Metastatic Breast |
| A022104 | The purpose of this study is to look at the effectiveness of two chemo regimens mFOLFOX6 or CAPOX vs mFOLFIRINOX in getting patients to remission. You must be diagnosed with stage 2 or 3 rectal cancer. | Cancer | Rectal |
| EAY191-N4 | The purpose of this study is to compare Selumetinib and Olaparib vs Selumetinib alone. You must be diagnosed with recurrent or persisent Ovarian or Endometiral cancer. Your cancer must have a RAS pathway mutation. | Cancer | Ovarian & Endometrial |
| URCC 18007 | A study see if Bupropion is effective for reducing cancer-related fatigue. You must have completed surgery, radiation and/or IV chemo at least 2 months prior to enrollment. | Cancer | All tumor types |
| A031803 | The purpose of this study is to determine the effectiveness of intravesical gemcitabine in combination with prembrolizumab. Patients must have been diagnosed with invasive bladder and already received chemo. | Cancer | Bladder |
| A031701 | The purpose of this study is to compare standard or dose dense gemcitabine and cisplatin chemo. You must have been diagnosed with muscle invasive bladder cancer. | Cancer | Bladder |
| EAY191-S3 ComboMATCH | The purpose of this study is to determine the effectiveness of Paclitaxel and Ipatasertib in patients who progressed within 6 months of taxane-based therapy. You must have a a AKT-Altered cancer. You must have a locally advanced, unresectable or metastatic cancer. | Cancer | Solid Tumors (non-breast) |
| S2209 | This study is for frail-intermediately fit newly diagnosed multiple myeloma patients. Your current lab values will be used to determine if you qualify for this study. This study compares different chemo regimens to determine the effectiveness of them. | Cancer | Multiple Myeloma |
| NRG-GI005 | The purpose of this study is to look at the tumor DNA with blood draws to determine risk of cancer recurrance. You must be diagnosed with Stage 2A colon cancer. | Cancer | Colon |
| A031702 | The purpose of this study is to look at the effectineness of cabozantinib combined with nivolumab and ipilimubmab. You must be diagnosed with a rare genitourinary tumor of the kidney, bladder, ureters or penis. | Cancer | Rare Genitourinary |
| ISPY 2 | This study uses the type of breast cancer you are diagnosed with to determine what treatment you are given. You must be diagnosed with stage 2 or stage 3 breast cancer. This study requires regular MRI's. | Cancer | Breast |
| GU012 | The purpose of this study is to compare standard immunotherapy with immunotherapy and radiation. You must be diagnosed with metastatic renal cell cancer and have not had surgery for this cancer. | Cancer | Metastatic Renal Cell |
| Bayer ON-TRK | The purpose of this study is to learn about the effectiveness of Vitrakvi in patients with TRK Fusion cancer. You must have a advanced solid tumor with a NTRK gene fusion. | Cancer | All tumor types |
| A031704 | The purpose of this study is to compare overall survival in patients treated with ipilimumab-nivolumab followed by either nivolumab or cabozantinib-nivolumab. You must be diagnosed with metastatic renal cell cancer. | Cancer | Metastatic Renal Cell |
| NRG-GI008 | The purpose of this study to use blood draws looking at the tumor DNA in the blood to determine need for chemotherapy. You must be diagnosed with stage 3 colon cancer. | Cancer | Colon |
Unsupported Browser! This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.